The road to chemotherapy-free treatment in chronic lymphocytic leukaemia
| Autor: | Nil Albiol, Carol Moreno, Miguel Arguello-Tomas |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Drug Cancer Research medicine.medical_specialty medicine.medical_treatment media_common.quotation_subject Disease Chemoimmunotherapy hemic and lymphatic diseases Internal medicine medicine Humans Molecular Targeted Therapy Precision Medicine media_common Randomized Controlled Trials as Topic Chemotherapy Lymphocytic leukaemia business.industry breakpoint cluster region Minimal residual disease Leukemia Lymphocytic Chronic B-Cell Immunotherapy IGHV@ business |
| Zdroj: | Current opinion in oncology. 33(6) |
| ISSN: | 1531-703X |
| Popis: | Purpose of review The treatment landscape of chronic lymphocytic leukaemia (CLL) has tremendously evolved in the last decades, from chemo to chemoimmunotherapy (CIT) and, eventually, to pathway inhibitors that target critical pathways for leukaemic cells survival. Also, treatment goals are moving towards achieving undetectable minimal residual disease with little toxicity. Recent findings We performed a thorough review of the history of treatment approvals by both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This review especially focuses on therapies that are currently approved by both agencies. The indications and particular characteristics of each drug are examined. Summary Currently available treatment approaches for CLL offer the opportunity to individualize therapy for every single patient with CLL. Inhibitors of B-cell receptor (BCR) signalling pathways and antiapoptotic proteins are nowadays the treatment of choice for most CLL patients, but CIT can be an option for younger and fit patients with low-risk disease [mutated IGHV, no del(11q) or del(17p)/TP53 mutations]. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|